Nuvation Bio Inc Warrants
NUVB.WS
NUVB.WS was delisted on the 10th of February, 2026.
20 hedge funds and large institutions have $2.81M invested in Nuvation Bio Inc Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.06% less ownership
Funds ownership: 1.87% → 1.81% (-0.06%)
9% less funds holding
Funds holding: 22 → 20 (-2)
32% less capital invested
Capital invested by funds: $4.11M → $2.81M (-$1.3M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$22K |
| 2 |
MA
MYDA Advisors
Woodmere,
New York
|
-$11K |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
-$486 |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$472 |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$83 |
NUVB.WS Hedge Fund Activity: Q3 2022 in Review
20 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio Inc Warrants (NUVB.WS) for Q3 2022, worth a combined $2.81M — down 32% from $4.11M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NUVB.WS and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.
The largest seller was Walleye Capital, exiting entirely with an estimated $22K sold.
- 20 institutional investors held Nuvation Bio Inc Warrants (NUVB.WS) as of Q3 2022, down from 22 in Q2 2022.
- Funds reported $2.81M of Nuvation Bio Inc Warrants stock for Q3 2022, down 32% quarter-over-quarter.
- 0 funds opened new Nuvation Bio Inc Warrants positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest Nuvation Bio Inc Warrants seller in Q3 2022 was Walleye Capital, an estimated $22K sold.
Based on aggregated 13F filings for Q3 2022.